- Welcome to the Wyoming Chapter of the American College of Cardiology
- Welcome to the Wyoming Chapter of the American College of Cardiology
Join your colleagues from Idaho, Nevada, New Mexico, Utah, and Wyoming on September 6th and 7th for a weekend of hot topics in cardiovascular care including heart failure, amyloid, prevention, clinician wellness, atrial fibrillation, and more! CME/CNE/MOC credits will be provided. We look forward to a wonderful weekend of networking and learning together at the Park City, Utah.
For more information and to register, please visit: ACC Rockies Chapter Meeting 2024
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- ACC CardiaCast: Conversations in Heart Failure: Extrapolate With Caution: A STEMI Shock Reality CheckIn this episode, Drs. Jenna Skowronski, Francesco Castagna and Saraschandra Vallabhajosyula unpack how assumptions drawn from ST-segment elevation myocardial infarction (STEMI) data may be leading us astray in broader shock management.
- Print Publication of ZENITH and SOUL Trials Spark Continued DialogueThe print publication of the ZENITH and SOUL trials – originally presented and published online during ACC.25 in Chicago – provides an additional platform for editorial commentary on their broader implication.
- ACC Submits Comments on FY 2026 IPPS Proposed RuleThe ACC submitted written comments on June 4 to the Centers for Medicare and Medicaid Services (CMS) on the fiscal year (FY) 2026 Inpatient Prospective Payment System (IPPS) proposed rule.
- CV and Bleeding Effects Comparable For Aspirin vs. Clopidogrel in Patients With ACS Within 1 Year Post PCICompared with clopidogrel monotherapy, cardiovascular and bleeding outcomes were similar with aspirin monotherapy beyond one month and up to one year after PCI in patients with acute coronary syndromes (ACS), whether or not they were at high bleeding risk (HBR) or had a STEMI or NSTE-ACS...
- Single-Dose Zilebesiran Injection Plus Antihypertensive Drug Reduces SBPA subcutaneous injection of the novel drug zilebesiran, when added to a standard antihypertensive agent, significantly reduces both 24-hour mean ambulatory and office systolic blood pressure (SBP) compared with placebo at three months in patients with uncontrolled hypertension...